Estimating heterogeneous treatment effects with survival outcomes via a deep survival learner

• URL: http://arxiv.org/abs/2604.10398v1
• Date: Sun, 12 Apr 2026 01:11:44 GMT
• Title: Estimating heterogeneous treatment effects with survival outcomes via a deep survival learner
• Abstract summary: Estimating heterogeneous treatment effects in survival settings is complicated by right censoring and the time-varying nature of the estimand.<n>We propose a deep survival learner for estimating heterogeneous treatment effects with right-censored outcomes.
• Score: 5.540352966241158
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Estimating heterogeneous treatment effects in survival settings is complicated by right censoring as well as the time-varying nature of the estimand. While the conditional average treatment effect (CATE) provides a natural target, most existing approaches focus on a single prespecified time point and do not account for the temporal trajectory, leading to instability in estimation. We propose a deep survival learner (DSL) for estimating heterogeneous treatment effects with right-censored outcomes. The method is based on a doubly robust pseudo-outcome whose conditional expectation identifies time-specific CATEs under standard assumptions. This construction remains unbiased if either the outcome model or the treatment assignment model is correctly specified, when properly accounting for censoring. To estimate CATEs over a clinically relevant time spectrum, DSL employs a multi-output deep neural network with shared representations, enabling joint estimation of treatment effect trajectories. From a theoretical perspective, we derive error bounds for both pointwise and joint estimation over time. We show that joint estimation can leverage temporal structure to control estimation error without incurring much additional approximation cost under smoothness conditions, leading to improved stability relative to separate estimation. Cross-fitting is incorporated to reduce overfitting and mitigate bias arising from flexible nuisance estimation. Simulation studies demonstrate favorable finite-sample performance, particularly under nuisance model misspecification. Applied to the Boston Lung Cancer Study, DSL reveals heterogeneity in the effects of perioperative chemotherapy across patient characteristics and over time.

Related papers

• Surv-IPTB: An Attention-Based Model for Estimating Individual Probability of Treatment Benefit with Survival Data [0.6882042556551609]
  The proposed model, called Surv-IPTB, directly quantifies the probability that a specific patient will experience extended survival time under treatment versus control.<n>We reformulate IPTB estimation as a binary classification problem, leveraging pairwise patient comparisons across treatment and control cohorts.<n>An attention mechanism with learnable query-key transformations enables flexible, data-driven aggregation of pairwise comparisons.
  arXiv  Detail & Related papers  (2026-08-06T17:13:44Z)
• KAPLAN: Kolmogorov-Arnold Prognostic Learnable Activation Networks for Survival Analysis [11.337632710839166]
  We introduce KAPLAN-HR for non estimation of the conditional hazard as a joint function of covariates and time.<n>A single-layer KAPLAN-HR model recovers a GAM, while deeper architectures capture interactions and time-varying effects through composition.<n>In evaluations over six clinical benchmark datasets, KAPLAN-HR matches or exceeds the predictive performance of established statistical and deep learning survival methods.
  arXiv  Detail & Related papers  (2026-05-21T22:30:03Z)
• Targeted learning of heterogeneous treatment effect curves for right censored or left truncated time-to-event data [1.360712433091342]
  We introduce surv-iTMLE, a learning procedure for estimating the difference in the conditional survival probabilities under two treatments.<n>Unlike existing estimators, surv-iTMLE accommodates both left truncation and right censoring while enforcing smoothness and boundedness of the estimated treatment effect curve over time.<n>We show that surv-iTMLE outperforms existing methods in terms of bias and smoothness of time-varying effect estimates in finite samples.
  arXiv  Detail & Related papers  (2026-03-27T15:08:07Z)
• Assessing the robustness of heterogeneous treatment effects in survival analysis under informative censoring [50.164756034797136]
  Dropout is common in clinical studies, with up to half of patients leaving early due to side effects or other reasons.<n>When dropout is informative, it introduces censoring bias, because of which treatment effect estimates are also biased.<n>We propose an assumption-lean framework to assess the robustness of conditional average treatment effect estimates in survival analysis when facing censoring bias.
  arXiv  Detail & Related papers  (2025-10-15T10:51:17Z)
• Penalized Empirical Likelihood for Doubly Robust Causal Inference under Contamination in High Dimensions [0.720409153108429]
  We propose a doubly robust estimator for the average treatment effect in low sample size equations.<n>We show that the proposed confidence interval remain efficient compared to those competing estimates.
  arXiv  Detail & Related papers  (2025-07-23T11:58:54Z)
• Beyond the ATE: Interpretable Modelling of Treatment Effects over Dose and Time [46.2482873419289]
  We propose a framework for modelling treatment effect trajectories as smooth surfaces over dose and time.<n>Our approach decouples the estimation of trajectory shape from the specification of clinically relevant properties.<n>We show that our method yields accurate, interpretable, and editable models of treatment dynamics.
  arXiv  Detail & Related papers  (2025-07-09T20:33:33Z)
• Estimating Long-term Heterogeneous Dose-response Curve: Generalization Bound Leveraging Optimal Transport Weights [54.65531750162626]
  Long-term treatment effect estimation is a significant but challenging problem in many applications.<n>Existing methods rely on ideal assumptions, such as no unobserved confounders or binary treatment, to estimate long-term average treatment effects.<n>We introduce an optimal transport weighting framework to align the long-term observational data to an auxiliary short-term experimental data.
  arXiv  Detail & Related papers  (2024-06-27T14:13:46Z)
• TCFimt: Temporal Counterfactual Forecasting from Individual Multiple Treatment Perspective [50.675845725806724]
  We propose a comprehensive framework of temporal counterfactual forecasting from an individual multiple treatment perspective (TCFimt) TCFimt constructs adversarial tasks in a seq2seq framework to alleviate selection and time-varying bias and designs a contrastive learning-based block to decouple a mixed treatment effect into separated main treatment effects and causal interactions. The proposed method shows satisfactory performance in predicting future outcomes with specific treatments and in choosing optimal treatment type and timing than state-of-the-art methods.
  arXiv  Detail & Related papers  (2022-12-17T15:01:05Z)
• Robust and Agnostic Learning of Conditional Distributional Treatment Effects [44.31792000298105]
  We provide a new robust and model-agnostic methodology for learning the conditional DTE (CDTE) for a class of problems.<n>Our method is model-agnostic in that it can provide the best projection of CDTE onto the regression model class.<n>We investigate the behavior of our proposal in simulations, as well as in a case study of 401(k) eligibility effects on wealth.
  arXiv  Detail & Related papers  (2022-05-23T17:40:31Z)
• SurvITE: Learning Heterogeneous Treatment Effects from Time-to-Event Data [83.50281440043241]
  We study the problem of inferring heterogeneous treatment effects from time-to-event data. We propose a novel deep learning method for treatment-specific hazard estimation based on balancing representations.
  arXiv  Detail & Related papers  (2021-10-26T20:13:17Z)
• CDSM -- Casual Inference using Deep Bayesian Dynamic Survival Models [3.9169188005935927]
  We have developed a causal dynamic survival model (CDSM) that uses the potential outcomes framework with the Bayesian recurrent sub-networks to estimate the difference in survival curves. Using simulated survival datasets, CDSM has shown good causal effect estimation performance across scenarios of sample dimension, event rate, confounding and overlapping.
  arXiv  Detail & Related papers  (2021-01-26T09:15:49Z)
• Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score [59.75318183140857]
  Estimating causal effects from randomized experiments is central to clinical research. Most methods for historical borrowing achieve reductions in variance by sacrificing strict type-I error rate control.
  arXiv  Detail & Related papers  (2020-12-17T21:10:10Z)
• Estimating heterogeneous survival treatment effect in observational data using machine learning [9.951103976634407]
  Methods for estimating heterogeneous treatment effect in observational data have largely focused on continuous or binary outcomes. Using flexible machine learning methods in the counterfactual framework is a promising approach to address challenges due to complex individual characteristics.
  arXiv  Detail & Related papers  (2020-08-17T01:02:14Z)
• Enabling Counterfactual Survival Analysis with Balanced Representations [64.17342727357618]
  Survival data are frequently encountered across diverse medical applications, i.e., drug development, risk profiling, and clinical trials. We propose a theoretically grounded unified framework for counterfactual inference applicable to survival outcomes.
  arXiv  Detail & Related papers  (2020-06-14T01:15:00Z)
• Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials [0.0]
  Increased patient heterogeneity can weaken the ability of common statistical approaches to detect treatment differences. A list of baseline covariates that have the potential to be prognostic for survival under either treatment is pre-specified. A conditional inference tree algorithm is used to segment the heterogeneous trial population into subpopulations of prognostically homogeneous patients. The impressive power-boosting performance of our proposed 5-step stratified testing and amalgamation routine (5-STAR) is illustrated.
  arXiv  Detail & Related papers  (2020-04-28T15:44:41Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.